ReviewDiagnostics (Basel, Switzerland)2025
The Promise of Infrared Spectroscopy in Liquid Biopsies for Solid Cancer Detection.
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Stalk Sign in Bladder Cancer: CEUS Versus MRI.Diagnostics (Basel, Switzerland) · 2026Article
- Glycan Fingerprint of Malignant Pleural Mesothelioma.International journal of molecular sciences · 2026Article
- Pre-Transplant Serum FTIRS Signatures as Predictive Biomarkers of Early Transient Pancreatic Graft Dysfunction in Simultaneous Pancreas-Kidney Transplantation.Life (Basel, Switzerland) · 2026Article
- Artificial Intelligence-Assisted Infrared Spectroscopy and Chemometrics for Enhanced Histopathology Screening of Micro- and Macrocancer Lesions.Analytical chemistry · 2026Article
- Vibrational spectroscopy in cellular and molecular pathology: From optical signatures to diagnostic insight.CytoJournal · 2026Article
- Non-invasive diagnosis of endometrioma through cervical swabs using Fourier transform infrared spectroscopy.Turkish journal of obstetrics and gynecology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attenuated total reflection-Fourier transform infrared (ATR-FTIR) spectroscopy has shown significant promise in the context of liquid biopsy, offering a potential tool for cancer diagnostics. Unlike traditional tissue biopsies, which may not fully capture the clonal heterogeneity of tumors, liquid biopsy reflects the dynamic state of the disease and its progression more comprehensively. Biofluids such as serum and plasma are low-cost, minimally invasive diagnostic media with well-established clinical uses. This review assesses the use of ATR-FTIR spectroscopy to detect biochemical changes in biofluids linked to various malignancies, including breast, ovarian, endometrial, prostate, bladder, kidney, pancreatic, colorectal, hepatic, esophageal, gastric, lung, and brain cancers. While ATR-FTIR offers the advantages of rapid, minimally invasive detection and real-time disease monitoring, its integration into clinical practice faces challenges, particularly in terms of reproducibility due to variability in sample preparation, spectral acquisition, and data processing. The translation of ATR-FTIR into routine diagnostics will require validation through large-scale cohort studies and multicenter trials to ensure its clinical reliability and effectiveness.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.